Medication and glycemic control

Editorial Board member Sanjay Kalra presents his view on the march toward greater integration of digital health technologies and how traditional approaches to diabetes management are already changing.

Nichol AD, Holle MJ, An R. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0170-6

Zivkovic M, Petrovski G, Bitoska I. Acta Diabetol 2018; Advance online publication. doi: 10.1007/s00592-018-1147-6

Diabetes and endocrinology Consultant and Advisory Board member Terence Pang highlights the benefits that a structured approach to glycemic goal setting can bring to your practice and patients with type 1 diabetes.

Haneda M et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0416-2

Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.

As the utility and availability of devices surges, so too do patient expectations. Advisory Board member Katharine Barnard provides key consultation questions to help determine your patients’ greatest needs and obstacles.

The AWARD-10 findings show significantly improved glycemic control in patients with type 2 diabetes who add the glucagon-like peptide-1 receptor agonist dulaglutide to any sodium-glucose cotransporter 2 inhibitor.

Experts review the evidence and best clinical practices of initiating and titrating insulin in patients with type 2 diabetes and provide guidance and practical recommendations for the healthcare community.

Horikawa Y et al. Diabetes Ther 2018; 9: 421. doi: 10.1007/s13300-018-0369-5

Kishimoto M, Tamada S, Oshiba Y. J Diabetes Metab Disord 2017; 16: 44. doi: 10.1186/s40200-017-0327-1

Editorial Board member Sanjay Kalra shares his pragmatic and practical suggestions on initiating, monitoring, and titrating suitable patients on U500 regular insulin.

Donihi AC. Curr Diab Rep 2017; 17: 52. doi: 10.1007/s11892-017-0876-1